Leukemia

Nipent European marketing authorizations acquired

Published in Cancer Weekly, March 23rd, 2004

SuperGen Inc. (SUPG) has acquired European marketing authorizations to the anticancer compound Nipent (pentostatin for injection) from Pfizer Inc. and plans to retain the exclusive European distributor for Nipent for the near term.

Nipent is currently approved as a single-agent treatment for patients with hairy cell leukemia and under investigational study for a number of hematological malignancies. Terms of the transaction were not disclosed.

In 1996, SuperGen purchased domestic distribution and marketing rights to Nipent from the Warner-Lambert Company, which was later acquired by Pfizer.

"As a result of this transaction with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry